Refine by
Copd Articles & Analysis
98 news found
Asthma remains a complex and multifactorial disease, with airway hyperresponsiveness to methacholine being a hallmark feature. A recent study by Rojas-Ruiz et al (2025) utilizes SCIREQ’s innovative physioLens (ex vivo) and flexiVent (in vivo) platforms to shed light on the interplay between lung tissue compliance and methacholine response, offering new insights into the mechanisms ...
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. ...
Vitalograph has joined forces with MedM Inc. to further enhance patient respiratory monitoring experience with digital health capabilities. The MedM health monitoring app is paired with Vitalograph’s Asthma-1 BT and Lung Monitor BT Smart devices. The app works as a digital asthma or lung function diary, helping users to better understand and manage their condition. Patient diaries like ...
It can aid in the diagnosis of asthma and COPD and can also help identify patients who are at risk of progression to COPD. [1] The tremoflo® C-100 assesses respiratory function through simple tidal breathing and can be a valuable tool when compiling a detailed picture of respiratory function. ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
” “I am also pleased to report that eNOfit™, our novel miniaturized mobile-wearable nitric oxide device designed to provide ’on-the-go’ treatment for patients suffering from severe COPD and ILD (pulmonary fibrosis), is scheduled to enter clinical trials in the next few months. ...
Having a treatment that can help patients breathe easier and live a better quality of life, without surgical intervention, will be a major step forward in COPD care in Japan.” Over 600,000 Japanese patients suffer from severe COPD, including approximately 100,000 patients with severe disease where hyperinflation causes them to remain symptomatic despite ...
The results demonstrated the high accuracy of BioMark’s quantitative metabolomic platform to identify early-stage lung cancer in retrospective plasma samples from individual with smoking history compared to participants suffering from other lung diseases including asthma, COPD, bronchiectasis and COVID. The poster is accessible on the Company website. ...
Chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, makes breathing difficult for millions of Americans who have been diagnosed with the condition. ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. ...
The Simeox device is an efficient and comfortable therapy for distal mucus clearance – for patients suffering from chronic lung conditions associated with chest congestion, such as bronchiectasis, cystic fibrosis, COPD, primary ciliary dyskinesia, severe asthma, etc. It can be used in the hospital or clinics, or autonomously at home. ...
Recent Highlights and Upcoming Milestones LungFit® PH Continue progress with limited release phase of commercial launch, making it the first and only nitric oxide generator, delivery and monitoring system available in the U.S., following FDA approval on June 28, 2022 to treat term and near-term neonates with hypoxic respiratory failure CE Mark anticipated to be received at the end of ...
Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. ...
For many families, November signals the start of the holiday season. It is a special time to gather with loved ones and check-in to make sure everyone is happy and healthy. November is also lung cancer awareness month. VisionGate wants to help you, your family and loved ones learn more about who is at risk, the impact, and the types of lung cancer. Because keeping yourself informed ...
Instead, it offers similar enhanced analysis capabilities for other lung diseases that aren’t necessarily cancer – such as COPD and asthma – but are still very debilitating for patients. ...
ByFluidda
Respiratory AI solutions from VIDA are used to assess the lung characteristics associated with chronic, complex lung disease, such as COVID-19 related lung damage, chronic obstructive pulmonary disease (COPD), interstitial lung disease, emphysema, and asthma. In addition to clinical applications, pharmaceutical companies rely on VIDA’s ISO 13485-certified core lab processes ...
FDA approval of generic OIDPs for Asthma and Chronic Obstructive Pulmonary Disease (COPD) using its proprietary in vitro and in silico service platform, SmartTrack™. ...
ByFluidda
The Company will be presenting clinical data using its quantitative metabolomic platform to identify early-stage lung cancer in retrospective plasma samples from individual with smoking history, or suffering from other lung diseases including asthma, COPD, bronchiectasis and COVID. The interim data analysis from 813 plasma samples will be presented during the ESMO Congress 2022 ...
The AeriSeal System is used to close collateral air channels in a target lung lobe of a patient with severe COPD/emphysema, making the patient eligible to then undergo Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Valves. ...
Elias is an internationally renowned lung specialist who has made seminal discoveries in lung cancer, pulmonary fibrosis, asthma and COPD. He has served as Chief of Pulmonary and Critical Care Medicine and Chairman of the Department of Internal Medicine at Yale School of Medicine and Yale New Haven Hospital. ...